Endotag-1

Pancreatic Adenocarcinoma

SynCore Biotechnology Co., Ltd.Phase 3Dormant

B

57/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 49/ 100
Competitive Position: 73/ 100

Competitive context

190 Active assets in the Pancreatic Adenocarcinoma cohort.

Asset / Sponsor	Phase	Rating
FLUOROURACILUM Jonsson Comprehensive Cancer Center	Phase 4	BBB
Docetaxel Bristol-Myers Squibb	Phase 2	BBB
Eloxatin Jonsson Comprehensive Cancer Center	Phase 4	BB
Irinotecan Jonsson Comprehensive Cancer Center	Phase 3	BB
Irinotecan Ipsen	Phase 3	BB

View all 50 →

Same molecule, other indications

Endotag-1 is also rated in:

Locally Advanced Pancreatic CancerDormant

B

Indicative ·

62 / 100

metastatic neoplasmDormant

B

Indicative ·

60 / 100

pancreatic neoplasmDormant

B

Indicative ·

57 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.